Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Methamphetamine-dependence: early-phase trial registry

6 of 19 indexed Methamphetamine-dependence trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #902 of 28,707 conditions by registered trial count.

19 US clinical trials · 6 currently recruiting · #902 of 28,707 conditions by registered trial count

Methamphetamine-dependence: 19 US clinical trials tracked, 6 recruiting.

Methamphetamine-dependence is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, Los Angeles, running 4 of these trials.

Enrollment posture brief

Registry condition methamphetamine-dependence

OPEN 6 | RECR 32% | LATE 2 | EARLY 10 | RANK #902 | SPON 4

Nearest open-share peer: Back Pain (32% recruiting · 38 trials)

Amyotrophic Lateral Sclerosi52.6%Anesthesia, Local42.1%Alcohol Consumption36.8%Methamphetamine-dependen (th…32%Attention Deficit Hyperactiv26.3%
Open-enrollment share among volume-matched conditions near Methamphetamine-dependence

Methamphetamine-dependence lists 6 open slots (32% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Methamphetamine-dependence on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Methamphetamine-dependence is recruiting below its size-band peers.

    6 of 19 indexed trials (31.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Methamphetamine-dependence research.

    University of California, Los Angeles accounts for 4 of 19 trials (21.1%). 13 distinct sponsors appear on at least one study for this condition label.

  3. Most Methamphetamine-dependence trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 19 trials that report a genuine target (sentinel values excluded). 15 of those (78.9%) plan for fewer than 100 participants.

  4. Methamphetamine-dependence research is mostly interventional.

    18 interventional and 1 observational studies make up this index (94.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 26Phase 32

Open and recent trials

19 total, page 1 of 1

RECRUITING NA 600 participants

Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives

Wake Forest University Health Sciences

NCT04927143

RECRUITING Phase 3 360 participants

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

National Institute on Drug Abuse (NIDA)

NCT06233799

RECRUITING Phase 2 300 participants

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

Evon Medics

NCT06434818

RECRUITING NA 50 participants

rTMS for Craving in Methamphetamine Use Disorder

Oregon Health and Science University

NCT03470480

RECRUITING Early Phase 1 40 participants

PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)

University of Utah

NCT05128071

RECRUITING Phase 3 29 participants

Creatine for Depressed Male and Female Methamphetamine Users

Montana State University

NCT02568878

ACTIVE NOT RECRUITING NA 40 participants

MHealth Incentivized Adherence Plus Patient Navigation

University of Washington

NCT06027814

ACTIVE NOT RECRUITING NA 30 participants

The Human Stress Response in a Simulated ED Setting

University of Arkansas

NCT04317482

ACTIVE NOT RECRUITING NA 30 participants

Inflammation in Methamphetamine and STIs (IMSTI)

University of California, Los Angeles

NCT05162391

COMPLETED Phase 2 210 participants

Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence

National Institute on Drug Abuse (NIDA)

NCT00520286

COMPLETED Phase 2 84 participants

Study of Medical Treatment for Methamphetamine Addiction

University of California, Los Angeles

NCT00833443

COMPLETED Phase 2 30 participants

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

Tong Lee

NCT01377662

COMPLETED Early Phase 1 24 participants

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

University of Kentucky

NCT01967381

COMPLETED Phase 2 20 participants

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

Seattle Institute for Biomedical and Clinical Research

NCT00284206

COMPLETED Phase 2 20 participants

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

University of California, Los Angeles

NCT01011829

COMPLETED NA 19 participants

Pilot TMS for Methamphetamine Use Disorder

Ryan M. Carnahan

NCT04449055

COMPLETED Phase 1 11 participants

Safety Interaction Trial Ibudilast and Methamphetamine

University of California, Los Angeles

NCT01217970

COMPLETED Phase 1 9 participants

Buspirone as a Candidate Medication for Methamphetamine Abuse

University of Kentucky

NCT01843205

COMPLETED 8 participants

Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study

University of Arkansas

NCT00653263

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 6
Phase 3 2

Named interventions

Most-linked intervention names on Methamphetamine-dependence records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Methamphetamine (Desoxyn®) Drug
1 trials
Ibudilast 50mg Drug
1 trials
Ibudilast 20mg Drug
1 trials
long-acting injectable risperidone Drug
1 trials
Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR Other
1 trials
OND-PR002 and MPh-IR Drug
1 trials
Transcranial Magnetic Stimulation--MPFC first, DPFC second Device
1 trials

US sites by state

Facility locations filed on Methamphetamine-dependence trials. A trial with sites in several states counts in each.

California 6 trials
Arkansas 3 trials
Washington 2 trials
Utah 2 trials
Oregon 2 trials
Kentucky 2 trials
Iowa 2 trials
Wisconsin 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Methamphetamine-dependence page

19 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Methamphetamine-dependence condition card totals 19 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.